Anti-D Dosing for Chronic ITP
For chronic ITP in Rh(D)-positive, non-splenectomized patients, administer anti-D immunoglobulin at 50 mcg/kg as a single intravenous dose, which can be repeated as needed based on platelet response and bleeding symptoms 1.
Key Dosing Parameters
Standard Dose
- 50 mcg/kg body weight administered intravenously
- Given as a single dose when platelet count drops or bleeding occurs
- Can be repeated at intervals based on clinical response 1, 2
Administration Details
- Route: Intravenous ONLY for ITP treatment (not intramuscular) 1
- Rate: 2 mL per 15-60 seconds
- Calculation: (50 mcg × body weight in kg) ÷ 300 mcg per syringe = number of syringes needed 1
Clinical Context from Guidelines
The 2019 ASH guidelines address anti-D primarily in the newly diagnosed pediatric ITP setting, where it can be used as first-line treatment in appropriate candidates 3. The 2011 ASH guidelines suggest a single dose of anti-D for Rh-positive, non-splenectomized children requiring treatment (grade 2B) 4.
Important caveat: While guidelines focus on newly diagnosed cases, the FDA-approved dosing for chronic ITP is well-established at 50 mcg/kg 1.
Expected Response
- Time to response: Median 3 days (can occur as early as 2 hours in some patients) 1, 5
- Response rate: 66-87% of patients achieve platelet count ≥30 × 10⁹/L with increase >20 × 10⁹/L 1, 6, 2
- Duration: Median 19-22 days per dose 1, 2
Maintenance Dosing Strategy
For patients requiring ongoing treatment:
- Repeat 50 mcg/kg doses when platelet count drops below 30 × 10⁹/L or with bleeding symptoms 6
- Some protocols use every 4 weeks for maintenance 7
- Weekly dosing (5-15 mcg/kg/week) has been reported in refractory cases, though this is lower than standard dosing 8
Critical Safety Considerations
Absolute Requirements
- Patient must be Rh(D)-positive
- Patient must be non-splenectomized
- Do NOT use if hemoglobin is already decreased from bleeding or if autoimmune hemolysis is present 4
Expected Hemolysis
- Mean hemoglobin decrease: 0.8 ± 0.4 g/dL 7
- Most patients experience mild hemolysis (61% have some Hb drop) 7
- Monitor closely: Serious intravascular hemolysis can occur, though it resolved completely in clinical trials 1
- Transfusion rarely needed with appropriate patient selection 6, 7
Monitoring Parameters
- Hemoglobin and reticulocyte count at baseline and after treatment
- Platelet count on days 1,3,7,14, and 21 (or as clinically indicated)
- Watch for chills, fever, increased bilirubin, headache 2
Alternative Dosing Considerations
Higher dose (75 mcg/kg): Some pediatric studies used 75 mcg/kg as a single dose with similar efficacy to 50 mcg/kg, but the FDA-approved and most widely validated dose remains 50 mcg/kg 5, 7, 9.
Intramuscular route: Recent data suggest IM anti-D (not FDA-approved for ITP) may be safer regarding intravascular hemolysis risk, but IV remains the standard approved route 10, 11.
When Anti-D is NOT First Choice
For chronic ITP (≥3 months duration) who are corticosteroid-dependent or non-responsive, current ASH guidelines prioritize:
- TPO receptor agonists (eltrombopag or romiplostim)
- Splenectomy
- Rituximab
Anti-D serves as a bridge therapy or for patients requiring intermittent treatment rather than continuous therapy 3.